Incobotulinumtoxin A Injection - An Overview

Drug Overview

Incobotulinumtoxin A injection is utilized to address chronic sialorrhea (persistent drooling or excessive salivation) in both adults and children aged two years and older. Additionally, it treats spasticity (muscle stiffness and tightness) in the arm muscles of children two years and older who do not have cerebral palsy (a condition that affects movement and balance).

For adults, Incobotulinumtoxin A treats spasticity in the arm muscles and blepharospasm (involuntary tightening of the eyelid muscles that may result in blinking, squinting, and abnormal eyelid movements). It is also effective in alleviating symptoms of cervical dystonia (spasmodic torticollis; involuntary tightening of the neck muscles that can lead to neck pain and abnormal head positions) and temporarily smoothing frown lines (wrinkles between the eyebrows) in adults.

Incobotulinumtoxin A injection belongs to a class of medications known as neurotoxins. When injected into salivary glands, it inhibits the nerve signals that cause excessive saliva production. When injected into a muscle, it blocks the nerve signals that lead to involuntary tightening and movement of the muscle. The FDA (Food and Drug Administration) approved it for intramuscular or intraglandular use in 2010.

For Patients

What Are the Clinical Indications for Incobotulinumtoxin A Injection?

Incobotulinumtoxin A is indicated for treating chronic sialorrhea, upper limb spasticity, cervical dystonia, blepharospasm, and glabellar lines in adult patients.

What Is the Dosage of Incobotulinumtoxin A Injection?

Treatment starts with a low dose, adjusted based on the response. While it helps manage symptoms, it does not cure the condition, and full effects may take days to weeks.

What Are the Things to Inform the Doctor Before Taking the Drug?

The patient must inform the doctor if they are on other medications before starting this drug. They should also inform them about the below-mentioned conditions:

• Pregnancy.

• Heart disease.

• Liver disease.

• Seizures.

• Kidney diseases.

• Stroke (brain attack).

• Cancer.

• Breastfeeding.

• Diabetes (blood sugar).

How Is Incobotulinumtoxin A Injection Administered?

Incobotulinumtoxin A injection is a powder mixed with a liquid administered by a doctor into the saliva glands or muscles. The doctor chooses the injection site to best treat the condition, with follow-up injections every three to four months.

What Are the Side Effects of Incobotulinumtoxin A Injection?

• Vision changes.

• Swelling of the eyelids.

• Eye pain or irritation.

• Seizures.

• Neck pain.

• Shortness of breath.

• Fainting or dizziness.

• Rash, hives, or itching.

• Nasal congestion, sore throat, or runny nose.

• Headache.

• Dry mouth.

• Dental or gum problems.

• Diarrhea.

• Joint, bone, or muscle pain.

• Dry eyes.

• Reduced blinking or effectiveness of blinking.

Missed Dose:

If a dose of Incobotulinumtoxin A injection is missed, contact the healthcare provider promptly for guidance on rescheduling the dose. Missing a dose may temporarily delay the treatment's effectiveness. Follow the doctor's instructions closely to ensure proper condition management, and avoid adjusting the schedule or dose without medical advice, as it could impact treatment outcomes.

Overdose:

If someone receives an excessive amount of Incobotulinumtoxin A injection or accidentally swallows the medication, symptoms of overdose typically do not manifest immediately. It is important to inform a doctor immediately if symptoms such as weakness, difficulty moving any part of the body, or breathing difficulties occur in the weeks following the injection. Prompt medical attention is crucial to managing any potential overdose effects effectively.

Storage:

Unopened vials of Incobotulinumtoxin A injection can be stored at room temperature, between 20 and 25 degrees Celsius, or in a refrigerator, at two to eight degrees Celsius. Ensure that the medication is not used after the expiration date printed on the vial.

For Doctors

Indication:

Incobotulinumtoxin A injection is an acetylcholine release inhibitor and neuromuscular blocking agent used to treat or improve chronic sialorrhea, upper limb spasticity, cervical dystonia, and blepharospasm previously treated with Ionabotulinumtoxin A.

Dose:

Incobotulinumtoxin A injection is administered as follows:

• For chronic sialorrhea, 100 units are divided between parotid and submandibular glands.

• For upper limb spasticity, initial dosing is individualized based on muscle size and severity, with treatments spaced at least every 12 weeks.

Dosing Considerations:

• Ensure the initial dose is tailored based on the patient's severity and previous treatment response.

• Adjust injection sites and total dose according to the specific muscle groups affected and their response.

• Monitor closely for adverse effects and adjust subsequent doses based on clinical efficacy and patient tolerance.

• Adhere to recommended treatment intervals to maintain optimal therapeutic outcomes and minimize the risk of over-treatment or complications.

What Are the Pharmacological Aspects of Incobotulinumtoxin A Injection?

Mechanism Of Action

Incobotulinumtoxin A is a neurotoxin derived from the bacterium Clostridium botulinum. It belongs to the class of botulinum toxins, which act by disrupting the release of acetylcholine at the neuromuscular junction.

Binding and Internalization:

• When Incobotulinumtoxin A is injected into muscle tissue, it binds to presynaptic nerve terminals at the neuromuscular junction. The binding occurs specifically to the synaptosome-associated protein (SNAP-25) on the neuronal membrane.

• SNAP-25 is essential for the fusion of synaptic vesicles containing acetylcholine with the presynaptic membrane, a crucial step in neurotransmitter release.

Inhibition of Neurotransmitter Release:

• Once bound, Incobotulinumtoxin A undergoes internalization via receptor-mediated endocytosis into the nerve terminal.

• Inside the neuron, the toxin undergoes a series of conformational changes that lead to its translocation across the endosomal membrane and eventual release into the cytoplasm.

Cleavage of SNARE Proteins:

• In the cytoplasm, Incobotulinumtoxin A enzymatically cleaves specific proteins known as SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. These include SNAP-25, which is cleaved at a particular site.

• Cleavage of SNAP-25 disrupts the assembly of the SNARE complex, a crucial step for synaptic vesicle fusion and acetylcholine release.

Blockade of Acetylcholine Release:

• By cleaving SNAP-25, Incobotulinumtoxin A prevents the fusion of synaptic vesicles with the presynaptic membrane.

• This blockade leads to a reduction in the release of acetylcholine into the synaptic cleft, inhibiting the transmission of nerve signals to the muscle fibers.

Muscle Relaxation and Therapeutic Effects:

• With reduced acetylcholine release, the affected muscle experiences temporary paralysis or weakening. This effect is localized to the muscles near the injection site.

• The therapeutic outcomes depend on the specific condition being treated:

  • Chronic Sialorrhea: Reduces saliva production by targeting salivary glands.
  • Upper Limb Spasticity: Alleviates muscle stiffness and spasticity in the arms.
  • Cervical Dystonia: Relieves muscle contractions in the neck that cause abnormal head positions and pain.
  • Blepharospasm: Diminishes involuntary eyelid contractions that lead to abnormal blinking and squinting.
  • Glabellar Lines: Temporarily smooths facial wrinkles by relaxing the muscles responsible for frown lines.

Duration and Reversibility:

• The effects of Incobotulinumtoxin A are temporary because new nerve terminals regenerate and form connections with the muscle fibers over time.

• Typically, the onset of action begins within a few days to a week after injection, reaching maximal effect within one to two weeks.

• The duration of effect varies but generally lasts for several months, after which muscle activity gradually returns as the toxin’s effects wear off.

Pharmacokinetics

• Absorption: The absorption process is slow, typically leading to peak serum concentrations being reached between 12 to 16 days post-injection. This delayed absorption pattern contrasts with other medications that exhibit faster uptake into the bloodstream. The gradual absorption contributes to the onset of therapeutic effects observed over several days to weeks following administration. This pharmacokinetic characteristic is integral to understanding the timing and duration of Incobotulinumtoxin A's clinical effects in treating conditions such as muscle spasticity, dystonia, and cosmetic concerns.

• Distribution: After absorption into the bloodstream following intramuscular injection, Incobotulinumtoxin A distributes widely throughout the body. Despite its systemic distribution, the toxin primarily remains localized at the injection site and adjacent tissues, where it exerts its therapeutic effects. This localization is crucial, as it ensures targeted action on specific muscle groups while minimizing systemic exposure and potential side effects elsewhere in the body. Importantly, Incobotulinumtoxin A does not cross the blood-brain barrier in significant amounts. This characteristic is beneficial in medical applications, as it limits the potential for central nervous system effects and reduces the risk of neurological complications beyond the intended treatment area. Thus, the distribution profile of Incobotulinumtoxin A supports its localized therapeutic use in addressing conditions like muscle spasticity, dystonia, and cosmetic concerns without widespread systemic impact.

• Metabolism: Metabolism of Incobotulinumtoxin A predominantly occurs through enzymatic degradation within the muscle tissue where it is injected and in the surrounding areas. Following its localization at the injection site, the toxin undergoes breakdown into smaller peptides and amino acids. These breakdown products are then processed and eliminated from the body through normal metabolic pathways. This metabolic process is crucial for the gradual clearance of Incobotulinumtoxin A from the systemic circulation, contributing to its gradual decrease in therapeutic effect over time. The enzymatic degradation and subsequent elimination of Incobotulinumtoxin A ensure that its effects are temporary and reversible, allowing for predictable treatment outcomes and management of potential adverse effects. Understanding the metabolism of Incobotulinumtoxin A is essential for optimizing dosing strategies and ensuring its safe and effective use in clinical practice for conditions such as muscle spasticity, dystonia, and cosmetic enhancements.

• Elimination: Incobotulinumtoxin A has a notable elimination profile characterized by a relatively long half-life, ranging from approximately 22 to 31 days. This prolonged half-life indicates that the toxin is slowly cleared from the body over time. The slow clearance is primarily attributed to its distribution and localization within muscle tissues, where it undergoes gradual enzymatic degradation. Following metabolism within the injected muscle and surrounding tissues, Incobotulinumtoxin A and its breakdown products are excreted from the body. The toxin is excreted mainly unchanged in urine, indicating renal elimination as a significant route of excretion. A portion of the toxin and its metabolites may also be eliminated through feces. The extended elimination half-life of Incobotulinumtoxin A contributes to the prolonged duration of its therapeutic effects observed clinically. This pharmacokinetic characteristic is crucial for understanding the dosing intervals and overall management of patients receiving treatment for conditions such as muscle spasticity, dystonia, and cosmetic enhancements. Monitoring the elimination kinetics helps healthcare providers tailor treatment schedules and optimize outcomes while minimizing the potential for systemic side effects.

Clinical Studies And Efficacy:

1. Chronic Sialorrhea:

• Double-blind, placebo-controlled study with 110 patients.

• Common adverse reactions: tooth extraction, dry mouth, diarrhea, hypertension.

• The majority of patients were male (71 percent) and white (99.5 percent).

2. Upper Limb Spasticity:

• Two placebo-controlled Phase 3 studies with 283 patients.

• Common adverse reactions (two percent): not specified in detail.

• Patients were predominantly male (58 percent) and white (84 percent).

3. Cervical Dystonia:

• Placebo-controlled Phase 3 trial with 159 patients.

• Common adverse events (five percent): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.

• The majority of patients were female (66 percent) and Caucasian (91 percent).

4. Glabellar Lines:

• Three placebo-controlled trials with 803 subjects.

• Common adverse reactions: headache (5.4 percent), facial paresis (0.7 percent), injection site hematoma (0.6 percent), eyelid edema (0.4 percent).

• Predominantly female subjects (88 percent).

What Are the Contraindications of Incobotulinumtoxin A Injection?

Incobotulinumtoxin A injection is contraindicated in individuals with a documented hypersensitivity to botulinum neurotoxin type A or any of the formulation's ingredients. Additionally, it should not be administered if there is an active infection at the intended injection sites.

Warnings and Precautions:

Spread of Toxin Effects:

• Incobotulinumtoxin A injection may lead to effects beyond the injection site, manifesting as asthenia, muscle weakness, double vision, blurred vision, drooping eyelids, and difficulty swallowing, speaking, or breathing.

• These effects can occur hours to weeks after injection and may be life-threatening, particularly in patients with predisposing conditions.

• Patients or caregivers should seek immediate medical attention for signs of swallowing, speech, or respiratory issues.

Lack of Interchangeability between Botulinum Toxin Products:

• The potency of Incobotulinumtoxin A units is specific to its formulation and assay method.

• These units cannot be compared or converted to units of other botulinum toxin products assessed with different assay methods.

Dysphagia and Breathing Difficulties:

• Treatment with Incobotulinumtoxin A can result in swallowing or breathing difficulties, especially in patients with pre-existing conditions.

• Weakening of injected muscles may affect swallowing or breathing. Additional respiratory muscles may be involved in distant effects.

• Dysphagia may persist, requiring measures like feeding tubes for nutrition and hydration. Aspiration risk increases, particularly in patients with compromised swallowing or respiratory function.

• Patients with neuromuscular disorders may face increased risks of severe dysphagia and respiratory issues.

Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated for Blepharospasm:

• Reduced blinking from Incobotulinumtoxin A injections can lead to corneal exposure, epithelial defects, and corneal ulcers, especially in patients with VII nerve disorders.

• Careful assessment of corneal sensation and avoidance of lower lid injections are essential to prevent ectropion.

• Caution is needed for patients at risk of narrow-angle glaucoma.

Risk of Ptosis in Patients Treated for Glabellar Lines:

• Avoid injection near the levator palpebrae superioris to minimize the risk of ptosis, especially in patients with prominent brow depressor complexes.

• Corrugator injections should be placed at least one centimeter above the bony supraorbital ridge.

Human Albumin and Transmission of Viral Diseases:

• Incobotulinumtoxin A contains human albumin derived from blood, with an extremely remote risk of transmitting viral diseases.

• Effective donor screening and manufacturing processes minimize the theoretical risk of Creutzfeldt-Jakob disease transmission.

Specific Considerations

• Pregnancy: The safety of Incobotulinumtoxin A injection during pregnancy is not well-established. It should only be used if the potential benefits outweigh the risks to the fetus. In animal studies, embryotoxic effects were observed at doses higher than the recommended human dose for cervical dystonia.

• Lactation: There is no available data on the presence of Incobotulinumtoxin A in human milk or its effects on breastfed infants or milk production. Consideration should be given to the benefits of breastfeeding, the clinical need for Incobotulinumtoxin A, and potential risks to the infant from both the medication and maternal conditions.

• Pediatric Use: The safety and effectiveness of Incobotulinumtoxin A in individuals under 18 years of age have not been established.

• Geriatric Use:

  • Chronic Sialorrhea: In studies involving patients with chronic sialorrhea, no significant differences in safety or effectiveness were observed between patients aged 65 years and older compared to younger patients.
  • Upper Limb Spasticity: Studies of upper limb spasticity noted similar findings, with no overall differences in safety or effectiveness observed between older and younger patients.
  • Cervical Dystonia: Older patients (over 65 years) treated with Incobotulinumtoxin A showed similar efficacy to younger patients, although increased sensitivity cannot be ruled out.
  • Blepharospasm: Geriatric patients (over 65 years old) with blepharospasm also demonstrated comparable safety and efficacy outcomes to younger patients.
  • Glabellar Lines: Limited clinical data exists for patients over 65 in glabellar line studies. However, safety profiles did not show an increased incidence of adverse events related to Incobotulinumtoxin A treatment in this age group.